A new head-to-head comparison of two tau PET tracers reveals significant differences in their ability to detect tau pathology across the aging and Alzheimer's disease spectrum. The study, published in The Lancet, found that [18F]MK6240 identified more individuals with tau pathology in both cognitively unimpaired and impaired individuals compared to [18F]flortaucipir. This finding has direct implications for patient stratification in clinical trials and therapeutic decision-making.
Tau pathology is a key proteinopathy in Alzheimer's disease, and its detection via PET imaging has become both an inclusion criterion and an outcome measure for recent clinical trials. The development of tau radioligands followed earlier work on amyloid-β plaque imaging, which revolutionized Alzheimer's research over 20 years ago. The choice of tracer may now influence which patients are enrolled and how treatment effects are measured.
The study, called HEAD, was a multicentre, prospective, cross-sectional, within-participant investigation. It systematically compared the two tracers in the same individuals, providing direct evidence of their differential performance. The findings suggest that [18F]MK6240 may be more sensitive for detecting early or subtle tau accumulation.
For clinical trials, the choice of tau PET tracer could alter enrollment numbers and the apparent efficacy of experimental therapies. A more sensitive tracer might allow earlier detection of pathology and better monitoring of treatment response. However, the study also notes that tracer selection must balance sensitivity with specificity to avoid false positives.
The authors caution that while [18F]MK6240 identified more cases, the clinical significance of these additional detections requires further study. Not all tau pathology detected by PET necessarily leads to cognitive decline, and the optimal tracer may depend on the specific research or clinical question being addressed.